Brief: Synact Pharma Announces Top Line Data From Expand P2b Clinical Trial

SynAct Pharma AB

04/09/2023 07:09

Sept 4 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * ANNOUNCES TOP LINE DATA FROM THE 12-WEEK EXPAND P2B
CLINICAL
TRIAL IN SEVERELY ACTIVE NEWLY DIAGNOSED RHEUMATOID ARTHRITIS
PATIENTS
    * RESOMELAGON (AP1189) DID NOT MEET PRIMARY ENDPOINT OF A
STATISTICALLY HIGHER RATE OF 20% IMPROVEMENT IN AMERICAN COLLEGE
OF RHEUMATOLOGY SCORE (ACR20) VERSUS PLACEBO AT 12 WEEKS
    * ALTHOUGH RESOMELAGON DID NOT DEMONSTRATE A CLEAR CLINICAL
BENEFIT ON PRIMARY ENDPOINT IT CONTINUED TO DEMONSTRATE A
FAVORABLE SAFETY PROFILE

Source text for Eikon:  ID:nMFN37nGtT 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))